GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concert Pharmaceuticals Inc (NAS:CNCE) » Definitions » Tangible Book per Share

Concert Pharmaceuticals (Concert Pharmaceuticals) Tangible Book per Share : $2.78 (As of Sep. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Concert Pharmaceuticals Tangible Book per Share?

Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding (EOP). Total tangible equity is calculated as the Total Stockholders Equity minus Preferred Stock minus Intangible Assets. Concert Pharmaceuticals's tangible book value per share for the quarter that ended in Sep. 2022 was $2.78.

Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Concert Pharmaceuticals Tangible Book per Share Historical Data

The historical data trend for Concert Pharmaceuticals's Tangible Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concert Pharmaceuticals Tangible Book per Share Chart

Concert Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Tangible Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.49 7.16 4.25 4.12 3.23

Concert Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Tangible Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.06 3.23 2.19 2.67 2.78

Competitive Comparison of Concert Pharmaceuticals's Tangible Book per Share

For the Biotechnology subindustry, Concert Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concert Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concert Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Concert Pharmaceuticals's Price-to-Tangible-Book falls into.



Concert Pharmaceuticals Tangible Book per Share Calculation

Concert Pharmaceuticals's Tangible Book Value Per Share for the fiscal year that ended in Dec. 2021 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(112.225-0-0)/34.739
=3.23

Concert Pharmaceuticals's Tangible Book Value Per Share for the quarter that ended in Sep. 2022 is calculated as

Tangible Book Value per Share=(Total Stockholders Equity-Preferred Stock-Intangible Assets)/Shares Outstanding (EOP)
=(133.272-0-0)/47.9347
=2.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total equity is a balance sheet item and equal to total assets less total liabilities of the company. Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.


Concert Pharmaceuticals  (NAS:CNCE) Tangible Book per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Concert Pharmaceuticals Tangible Book per Share Related Terms

Thank you for viewing the detailed overview of Concert Pharmaceuticals's Tangible Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Concert Pharmaceuticals (Concert Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
65 Hayden Avenue, Suite 3000N, Lexington, MA, USA, 02421
Concert Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company aims to discover and develop small-molecule drugs by incorporating new elements into known molecules or by leveraging the currently approved drugs to be used for new treatments. The pipeline consists of small molecules designed for oral administration to cure cystic fibrosis, inflammation, narcolepsy, residual schizophrenia, major depressive disorder, and Alzheimer's agitation.
Executives
James V Cassella officer: Chief Development Officer 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Marc A. Becker officer: CFO, PFO 175 CROSSING BLVD., 4TH FLOOR, FRAMINGHAM MA 01702
Nancy Stuart officer: Chief Operating Officer 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Jeffrey A Munsie officer: Chief Legal Officer CONCERT PHARMACEUTICALS, INC., 65 HAYDEN AVENUE, SUITE 3000N, LEXINGTON MA 02421
Roger D Tung director, officer: Chief Executive Officer 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Peter Barton Hutt director
Thomas G Auchincloss director C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Richard Aldrich director 1365 MAIN STREET, WALTHAM MA 02451
Heek Christi Van director 4001 MIRANDA AVENUE, PALO ALTO CA 94304
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jesper Hoeiland director C/O RADIUS HEALTH, INC., 950 WINTER STREET, WALTHAM MA 02451
Ronald W Barrett director C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Wilfred E Jaeger director C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511

Concert Pharmaceuticals (Concert Pharmaceuticals) Headlines

From GuruFocus

This Insider Just Sold Shares of Concert Pharmaceuticals Inc

By GuruFocus Research GuruFocus Editor 01-10-2023

Concert Pharmaceuticals Announces Pricing of Public Offering

By Business Wire Business Wire 06-02-2022